SAB Biotherapeutics, Inc. SABS

3.29 (0.06) (1.79%) as of 25 Sep
Market cap
$304.8M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '17
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 —
P/S ratio
— 21.57 17.26 1.18 3.51 0.00 —
P/FCF ratio
— 0.00 0.00 0.00 0.00 0.00 —
P/Operating CF
— (3.68) (2.87) (18.19) (43.77) (150,140.83) —
P/B ratio
— 1.35 0.67 0.91 5.54 93,838.02 —
EV/Sales
— 10.83 (6.47) 0.73 2.92 0.00 —
EV/EBITDA
— 0.00 0.42 0.00 0.00 0.00 —
EV/FCF
— (0.51) 0.57 (0.68) (19.84) 0.00 —
Current Ratio
9.46 2.98 5.45 1.47 1.90 3.11 —
Net Debt/EBITDA
2.03 0.46 1.55 0.42 3.05 (0.40) —
Debt/Equity
0.02 0.13 0.06 0.13 0.10 0.11 —
ROE
4.80% (81.92%) (95.51%) (53.85%) (44.21%) 51.88% —
ROA
3.93% (53.23%) (62.58%) (28.39%) (24.91%) 71.17% —
ROIC
(52.73%) (316.08%) (573.17%) (89.55%) (302.49%) 42.13% —
Return on Tangible Assets
4.11% (109.38%) (62.21%) (61.74%) (35.68%) 52.61% —
Average Days of Receivables
0.00 15.18 0.00 84.85 48.03 135.92 —
Earnings Yield
— (97.10%) (110.63%) (65.84%) (8.03%) 0.00% —
Free Cash Flow Yield
— (98.65%) (65.39%) (90.31%) (4.19%) 0.00% —
Free Cash Flow per Share
(2.37) (3.74) (4.58) (5.87) (3.28) (1.07) —
Book value per Share
7.84 2.80 10.38 7.14 14.10 15.36 —
Free Cash Flow
(45.71) (34.63) (25.27) (25.55) (8.96) (2.72) —
EV/EBIT
— 0.00 0.38 0.00 0.00 0.00 —
Other line items

Show all line items

Columns are period end dates